53.48
price up icon2.96%   1.54
after-market Dopo l'orario di chiusura: 53.30 -0.18 -0.34%
loading
Precedente Chiudi:
$51.94
Aprire:
$51.87
Volume 24 ore:
1.46M
Relative Volume:
0.57
Capitalizzazione di mercato:
$10.22B
Reddito:
$217.77M
Utile/perdita netta:
$-438.86M
Rapporto P/E:
-22.19
EPS:
-2.41
Flusso di cassa netto:
$-456.33M
1 W Prestazione:
+5.59%
1M Prestazione:
+3.32%
6M Prestazione:
+61.96%
1 anno Prestazione:
+115.65%
Intervallo 1D:
Value
$51.87
$53.81
Intervallo di 1 settimana:
Value
$48.78
$53.81
Portata 52W:
Value
$21.72
$54.60

Bridgebio Pharma Inc Stock (BBIO) Company Profile

Name
Nome
Bridgebio Pharma Inc
Name
Telefono
(650) 391-9740
Name
Indirizzo
3160 PORTER DR., PALO ALTO, CA
Name
Dipendente
730
Name
Cinguettio
Name
Prossima data di guadagno
2024-10-31
Name
Ultimi documenti SEC
Name
BBIO's Discussions on Twitter

Confronta BBIO con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
BBIO
Bridgebio Pharma Inc
53.48 9.93B 217.77M -438.86M -456.33M -2.41
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
404.21 100.41B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
599.94 59.59B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
460.65 59.77B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
767.33 45.14B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
335.16 37.42B 3.81B -644.79M -669.77M -6.24

Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-07-30 Ripresa Raymond James Outperform
2025-07-21 Iniziato Truist Buy
2025-07-14 Iniziato Jefferies Buy
2025-07-09 Aggiornamento Oppenheimer Perform → Outperform
2025-06-17 Iniziato Wolfe Research Outperform
2025-03-31 Iniziato Redburn Atlantic Buy
2024-10-16 Iniziato Scotiabank Sector Outperform
2024-10-03 Iniziato Oppenheimer Perform
2024-09-04 Iniziato Piper Sandler Overweight
2024-03-21 Ripresa Raymond James Outperform
2024-01-31 Iniziato BMO Capital Markets Market Perform
2023-12-08 Iniziato Wells Fargo Overweight
2023-11-07 Iniziato Citigroup Buy
2023-10-24 Iniziato Cantor Fitzgerald Overweight
2023-07-18 Downgrade Jefferies Buy → Hold
2023-04-19 Iniziato Evercore ISI Outperform
2023-02-06 Iniziato Cowen Outperform
2021-12-27 Reiterato Mizuho Buy
2021-12-27 Reiterato SVB Leerink Outperform
2021-09-10 Aggiornamento BofA Securities Neutral → Buy
2021-05-21 Iniziato UBS Buy
2021-03-22 Reiterato Goldman Buy
2021-02-22 Ripresa JP Morgan Overweight
2021-02-09 Ripresa Goldman Buy
2021-01-11 Reiterato H.C. Wainwright Buy
2020-12-10 Reiterato H.C. Wainwright Buy
2020-06-25 Iniziato BofA/Merrill Neutral
2020-05-19 Iniziato BTIG Research Buy
2020-04-13 Iniziato H.C. Wainwright Buy
2020-02-19 Iniziato Mizuho Buy
2019-07-26 Iniziato Raymond James Outperform
2019-07-22 Iniziato BMO Capital Markets Outperform
2019-07-22 Iniziato Goldman Buy
2019-07-22 Iniziato JP Morgan Overweight
2019-07-22 Iniziato Jefferies Buy
2019-07-22 Iniziato Piper Jaffray Overweight
2019-07-22 Iniziato SVB Leerink Outperform
Mostra tutto

Bridgebio Pharma Inc Borsa (BBIO) Ultime notizie

pulisher
11:36 AM

Hypoparathyroidism Market to Experience Notable Growth in Forecast Span by 2034, DelveInsight Predicts | Bridgebio/Calcil ytix Therapeutics, Ascendis Pharma, EnteraBio, Shire - Barchart.com

11:36 AM
pulisher
09:33 AM

Pattern recognition hints at BridgeBio Pharma Inc. upsideForecast Cut & Long Hold Capital Preservation Tips - newser.com

09:33 AM
pulisher
07:24 AM

How big funds are accumulating BridgeBio Pharma Inc. (2CL) stockDollar Strength & Consistent Return Investment Signals - newser.com

07:24 AM
pulisher
06:14 AM

Real time breakdown of BridgeBio Pharma Inc. stock performanceJuly 2025 Momentum & Short-Term High Return Strategies - newser.com

06:14 AM
pulisher
Sep 30, 2025

Why BridgeBio Pharma Inc. (2CL) stock could outperform next yearJuly 2025 Update & Expert Curated Trade Ideas - newser.com

Sep 30, 2025
pulisher
Sep 30, 2025

Analyzing drawdowns of BridgeBio Pharma Inc. with statistical toolsTrade Volume Report & Reliable Intraday Trade Alerts - newser.com

Sep 30, 2025
pulisher
Sep 30, 2025

What earnings revisions data tells us about BridgeBio Pharma Inc.2025 Market Overview & Weekly Market Pulse Updates - newser.com

Sep 30, 2025
pulisher
Sep 30, 2025

How buybacks impact BridgeBio Pharma Inc. stock valueWeekly Trade Analysis & Growth Oriented Trading Recommendations - newser.com

Sep 30, 2025
pulisher
Sep 29, 2025

Is BridgeBio Pharma Inc a good long term investmentMarket Sentiment Surveys & Access Free Tools and Start Investing - earlytimes.in

Sep 29, 2025
pulisher
Sep 29, 2025

What MACD and RSI say about BridgeBio Pharma Inc.Trade Entry Report & Verified Swing Trading Watchlist - newser.com

Sep 29, 2025
pulisher
Sep 29, 2025

Why Is BridgeBio Stock Gaining Monday?BridgeBio Pharma (NASDAQ:BBIO) - Benzinga

Sep 29, 2025
pulisher
Sep 29, 2025

Moss Adams Wealth Advisors LLC Has $1.04 Million Stock Position in BridgeBio Pharma, Inc. $BBIO - MarketBeat

Sep 29, 2025
pulisher
Sep 29, 2025

BridgeBio Pharma, Inc. (BBIO) Stock Analysis: A Biotech Powerhouse with a 32.50% Potential Upside - DirectorsTalk Interviews

Sep 29, 2025
pulisher
Sep 29, 2025

BridgeBio Pharma Says Drug Reduced Death, Hospitalization in Cardiomyopathy Patients After 1 Month - MarketScreener

Sep 29, 2025
pulisher
Sep 29, 2025

Will breakout in BridgeBio Pharma Inc. lead to full recovery2025 Market WrapUp & Stepwise Trade Signal Guides - newser.com

Sep 29, 2025
pulisher
Sep 28, 2025

What analysts say about BridgeBio Pharma Inc stockEarnings Beat Highlights & Small Budget Investment Tips - earlytimes.in

Sep 28, 2025
pulisher
Sep 28, 2025

BridgeBio (BBIO) Unveils Positive Results in ATTRibute-CM Study - GuruFocus

Sep 28, 2025
pulisher
Sep 28, 2025

BridgeBio Pharma says Acoramidis reduces CVM or CVH risk by 49% through month 30 - MarketScreener

Sep 28, 2025
pulisher
Sep 28, 2025

BridgeBio Pharma Reports Positive Results from ATTRibute-CM Study, Demonstrating Significant Reduction in Cardiovascular Outcomes with Acoramidis - Quiver Quantitative

Sep 28, 2025
pulisher
Sep 28, 2025

53 Heart Events Prevented Per 100 Patients: BridgeBio's Acoramidis Shows Powerful Early Benefits in ATTR-CM - Stock Titan

Sep 28, 2025
pulisher
Sep 28, 2025

What technical models suggest about BridgeBio Pharma Inc.’s comebackJuly 2025 Review & Consistent Income Trade Ideas - newser.com

Sep 28, 2025
pulisher
Sep 28, 2025

BridgeBio Pharma Inc Stock Analysis and ForecastPortfolio Allocation Tips & Smart Beta Strategies That Actually Work - earlytimes.in

Sep 28, 2025
pulisher
Sep 27, 2025

Best data tools to analyze BridgeBio Pharma Inc. stockStop Loss & Stepwise Swing Trade Plans - newser.com

Sep 27, 2025
pulisher
Sep 25, 2025

H.C. Wainwright Reiterates a Buy on BridgeBio Pharma (BBIO) - MSN

Sep 25, 2025
pulisher
Sep 24, 2025

Retirement Income Solutions Inc Acquires Shares of 5,000 BridgeBio Pharma, Inc. $BBIO - MarketBeat

Sep 24, 2025
pulisher
Sep 24, 2025

BridgeBio Pharma’s Encaleret Shows Positive Phase 2 Results, Normalizes Calcium in Post-Surgical Hypoparathyroidism - Yahoo Finance

Sep 24, 2025
pulisher
Sep 23, 2025

Atle Fund Management AB Grows Stock Position in BridgeBio Pharma, Inc. $BBIO - MarketBeat

Sep 23, 2025
pulisher
Sep 23, 2025

Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail

Sep 23, 2025
pulisher
Sep 23, 2025

Assenagon Asset Management S.A. Has $15.13 Million Stake in BridgeBio Pharma, Inc. $BBIO - MarketBeat

Sep 23, 2025
pulisher
Sep 23, 2025

Strs Ohio Makes New Investment in BridgeBio Pharma, Inc. $BBIO - MarketBeat

Sep 23, 2025
pulisher
Sep 22, 2025

BridgeBio to Present Additional Cardiovascular Outcomes - GlobeNewswire

Sep 22, 2025
pulisher
Sep 22, 2025

BridgeBio Pharma to Present Key Clinical Trial Findings at Heart Failure Society of America Annual Scientific Meeting 2025 - Quiver Quantitative

Sep 22, 2025
pulisher
Sep 22, 2025

BridgeBio to Present Additional Cardiovascular Outcomes Data from ATTRibute-CM at the HFSA Annual Scientific Meeting 2025 - The Manila Times

Sep 22, 2025
pulisher
Sep 22, 2025

New Cardiovascular Outcomes Data: BridgeBio's Acoramidis Shows Impact on ATTR-CM Patient Survival - Stock Titan

Sep 22, 2025
pulisher
Sep 22, 2025

BridgeBio Pharma, Inc. (BBIO) Stock Analysis: Exploring a Biotech Powerhouse with 24% Upside Potential - DirectorsTalk Interviews

Sep 22, 2025
pulisher
Sep 21, 2025

Risks To Shareholder Returns Are Elevated At These Prices For BridgeBio Pharma, Inc. (NASDAQ:BBIO) - 富途牛牛

Sep 21, 2025
pulisher
Sep 21, 2025

Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat

Sep 21, 2025
pulisher
Sep 21, 2025

BridgeBio Pharma, Inc. $BBIO Stock Position Lifted by Intech Investment Management LLC - MarketBeat

Sep 21, 2025
pulisher
Sep 20, 2025

Leerink Partners Maintains a Buy on BridgeBio Pharma (BBIO) With a $56 PT - MSN

Sep 20, 2025
pulisher
Sep 20, 2025

Fed Watch: Should value investors consider BridgeBio Pharma IncQuarterly Trade Report & Capital Efficient Trading Techniques - خودرو بانک

Sep 20, 2025
pulisher
Sep 19, 2025

BridgeBio Pharma (NASDAQ:BBIO) Earns Buy Rating from HC Wainwright - MarketBeat

Sep 19, 2025
pulisher
Sep 19, 2025

Aug Mood: What is the Moat Score of BridgeBio Pharma IncWeekly Trade Analysis & Weekly Watchlist for Hot Stocks - خودرو بانک

Sep 19, 2025
pulisher
Sep 19, 2025

BridgeBio Pharma, Inc. (NASDAQ:BBIO) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat

Sep 19, 2025

Bridgebio Pharma Inc Azioni (BBIO) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$36.32
price up icon 2.95%
$86.70
price up icon 2.23%
$31.77
price up icon 3.59%
$102.21
price up icon 3.64%
$147.28
price up icon 2.27%
biotechnology ONC
$335.16
price down icon 1.63%
Capitalizzazione:     |  Volume (24 ore):